OBJECTIVE: To investigate the protective effect of infliximab on ischemia-reperfusion (I/R) injury of the rat kidney. METHODS: Twenty-eight male Wistar albino rats were divided into four groups: sham-operated, I/R, I/R with infliximab administered before ischemia [I/R + infliximab (bi)], and I/R with infliximab administered before reperfusion [I/R + infliximab (br)]. After a right nephrectomy to produce damage, the left renal vessels were occluded for 60 min, followed by 24-h reperfusion in rats. Changes in the rat kidney were observed by measuring the tissue levels of malondialdehyde (MDA), myeloperoxidase (MPO), glutathione (GSH), and superoxide dismutase (SOD) and by evaluating hematoxylin-eosin (H&E)-stained and periodic acid-Schiff (PAS) sections. RESULTS: The MDA and MPO levels in the I/R group were significantly higher than in the other groups (p < 0.05), and the SOD and GSH levels in the I/R + infliximab (bi) and I/R + infliximab (br) groups were significantly higher than in the I/R group (p < 0.05). However, histological examination revealed that the I/R + infliximab (bi) group and the I/R + infliximab (br) group had significantly fewer tubular changes and interstitial inflammatory cell infiltration than the I/R group. CONCLUSION: These results show that infliximab may protect against I/R injury in the rat I/R model.
OBJECTIVE: To investigate the protective effect of infliximab on ischemia-reperfusion (I/R) injury of the rat kidney. METHODS: Twenty-eight male Wistar albino rats were divided into four groups: sham-operated, I/R, I/R with infliximab administered before ischemia [I/R + infliximab (bi)], and I/R with infliximab administered before reperfusion [I/R + infliximab (br)]. After a right nephrectomy to produce damage, the left renal vessels were occluded for 60 min, followed by 24-h reperfusion in rats. Changes in the rat kidney were observed by measuring the tissue levels of malondialdehyde (MDA), myeloperoxidase (MPO), glutathione (GSH), and superoxide dismutase (SOD) and by evaluating hematoxylin-eosin (H&E)-stained and periodic acid-Schiff (PAS) sections. RESULTS: The MDA and MPO levels in the I/R group were significantly higher than in the other groups (p < 0.05), and the SOD and GSH levels in the I/R + infliximab (bi) and I/R + infliximab (br) groups were significantly higher than in the I/R group (p < 0.05). However, histological examination revealed that the I/R + infliximab (bi) group and the I/R + infliximab (br) group had significantly fewer tubular changes and interstitial inflammatory cell infiltration than the I/R group. CONCLUSION: These results show that infliximab may protect against I/R injury in the rat I/R model.
Authors: Aly M Abdelrahman; Yousuf M Al Suleimani; Priyadarsini Manoj; Mohammed Ashique; Badreldin H Ali; Nicole Schupp Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2019-09-09 Impact factor: 3.000
Authors: Hoda E Mohamed; Mervat E Asker; Mohammed M Keshawy; Rehab A Hasan; Yasmin K Mahmoud Journal: Mol Cell Biochem Date: 2020-01-13 Impact factor: 3.842
Authors: Philipp Stiegler; Michael Sereinigg; Andreas Puntschart; Andrea Bradatsch; Thomas Seifert-Held; Iris Wiederstein-Grasser; Bettina Leber; Elke Stadelmeyer; Nadia Dandachi; Siglinde Zelzer; Florian Iberer; Vanessa Stadlbauer Journal: J Transl Med Date: 2013-10-02 Impact factor: 5.531